Charles River Laboratories Announces Updates to Oncology Business
May 16 2017 - 8:00AM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL)
recently announced updates to its expanding oncology discovery
business, including significant additions to its online Tumor Model
Compendium. The Compendium provides oncology researchers with a
resource to identify and locate targeted, suitable patient-derived
xenografts (PDXs) based on specific histology and molecular
properties, and now includes additional molecular characteristics
for syngeneic models.
“The use of a human tumor graft in a humanized model represents
the future of immuno-oncology research,” said Birgit Girshick,
Corporate Senior Vice President, Global Discovery, at Charles
River. “A model that more closely mirrors human immune systems
allows researchers to conduct groundbreaking studies more
efficiently and effectively, with the goal of developing more
translational therapies. Utilizing the Tumor Model Compendium,
oncology researchers can identify the exact tumor model and target
for their research, getting them that much closer to that
goal.”
Charles River has more than 450 fully characterized proprietary
PDXs in its portfolio, which represents all major tumor histotypes,
and provides extensive background and characterization for oncology
research. The most recent Compendium update expands the existing
tumor model collection to include:
- Whole-exome mutations determined by
Next-Generation Sequencing
- Gene copy number variations determined
by using Affymetrix Genome-Wide Human SNP Array 6.0
- Gene expression determined by using
Affymetrix Human Genome U133 Plus 2.0 Array
Recognizing the importance of selecting the appropriate tumor
model for in vivo and in vitro oncology, Charles River partnered
with OcellO to further expand their capabilities with PDX models.
Through their agreement, OcellO utilizes human tumor material from
Charles River PDX models and applies it in their 3D cell culture
drug screening platform. This high-throughput platform enables the
growth of micro-tumors in a natural extracellular matrix
environment and uses automated 3D imaging to analyze the effects of
small molecules and antibodies on tumor development.
“The extended range of tumor subtypes and high level of
annotation of Charles River’s PDX Compendium enables the selection
of the optimum tumor models with the most appropriate mutational
profile for in vivo studies,” said Leo Price, CEO and founder of
OcellO. “The use of the same PDX tumor cells in OcellO's in vitro
3D culture platform enables pre-screening of tumor models with test
compounds in a highly translational high-throughput platform.”
In addition to utilizing the Compendium in integrated client
relationships, recent tumor model updates have also enhanced
scientific presentations. At the 2017 AACR Annual Meeting, a
meeting which highlights the advances in cancer science and
medicine from institutions all over the world, Charles River
presented three posters highlighting the enhancement of certain
models for oncology drug discovery:
- Whole-exome somatic mutation
analysis of mouse cancer models and implications for preclinical
immunomodulatory drug development (available here.)
- Humanized single mouse trial: A
preclinical platform feasible for immune-oncology drug screening
and translational biomarker development (available here.)
- In vitro PDX models: 3D cultured
patient-derived tumors for compound evaluation (in conjunction
with OcellO, available here.)
Charles River’s extensive portfolio of oncology products and
services, including studies in human xenograft, syngeneic,
humanized immunotherapy research models, flow cytometry, and
IVIS® imaging services, was strengthened by the acquisition of
Oncotest GmbH. Now known as Charles River Discovery Research
Services Germany GmbH, the company is a Freiburg, Germany-based
organization with a specialization in PDX models with more than 25
years of experience. To address the increasing importance of
immuno-oncology, in April 2017 Charles River announced the
availability of its triple-immunodeficient mouse model, known as
the NCG model.
To learn more about Charles River’s oncology research
capabilities, visit www.criver.com.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170516005573/en/
Charles River Laboratories International, Inc.Investor
Contact:Susan E. Hardy, 781-222-6190Corporate Vice President,
Investor Relationssusan.hardy@crl.comorMedia Contact:Amy
Cianciaruso, 781-222-6168Corporate Vice President, Public
Relationsamy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2023 to Apr 2024